Video Experimental Relacionado
Updated: Feb 10, 2026
09:36
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
Published on: April 10, 2018
26.3K
ARN no codificante Nanotransportadores troyanos en CCR: Encrucijadas mecanicistas y desafíos terapéuticos
Mingrong Cheng1, Yucheng Ni1, Wei Zhang1
1Department of General Surgery, Nanxiang Branch of Ruijin Hospital, Shanghai 201802, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|February 8, 2026
Resumen
Un novedoso sistema "Caballo de Troya" a nanoescala se dirige a las células madre cancerosas y a las vías de transición epitelio-mesénquima para superar la quimiorresistencia en el cáncer colorrectal (CCR). Este método de administración avanzado mejora las nanoterapias de ARN no codificante (ARNnc) para obtener mejores resultados de tratamiento.
Área de la Ciencia:
- Oncología
- Nanomedicina
- Biología Molecular
Sus antecedentes:
- La quimiorresistencia del cáncer colorrectal (CCR) es un importante desafío clínico, impulsado por las células madre cancerosas (CCE) y la transición epitelio-mesénquima (EMT).
- Los ARN no codificantes (ARNnc) son reguladores clave en la quimiorresistencia del CCR, lo que presenta objetivos terapéuticos.
- La administración eficaz de ARNnc sigue siendo un obstáculo importante para la aplicación clínica.
Objetivo del estudio:
- Revisar el papel de los ARNnc en la quimiorresistencia del CCR.
- Detallar el diseño y la eficacia de un sistema de administración de fármacos "Caballo de Troya" a nanoescala para terapias basadas en ARNnc.
- Destacar el potencial de este sistema para superar la quimiorresistencia del CCR.
Principales métodos:
- Revisión sistemática de la regulación mediada por ARNnc en la quimiorresistencia del CCR.
- Análisis detallado de la estrategia de triple direccionamiento del sistema "Caballo de Troya" a nanoescala (niveles tisular, celular y molecular).
- Exploración de terapias combinadas sinérgicas y capacidades teranósticas.
Principales resultados:
- El sistema "Caballo de Troya" demuestra una administración precisa a las CCE y a las células quimiorresistentes.
- Se dirige eficazmente a las vías de la estirpe celular, la EMT y la quimiorresistencia.
- El sistema facilita las terapias combinadas multimodales e integra funciones teranósticas.
Conclusiones:
- El sistema de administración de fármacos "Caballo de Troya" a nanoescala ofrece una estrategia prometedora para superar la quimiorresistencia del CCR mediada por ARNnc.
- Este enfoque tiene el potencial de avanzar en la traducción clínica de las nanoterapias de ARNnc.
- La integración de tratamientos sinérgicos y teranósticos mejora la eficacia y el seguimiento terapéuticos.
Videos de Conceptos Relacionados
02:39lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
02:39lncRNA - Long Non-coding RNAs
3.7K
3.7K
01:32RNA Splicing
60.7K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.7K
02:53Ribosomal RNA Synthesis
14.9K
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
14.9K
01:29Nursing Code of Ethics
4.6K
The Nursing Code of Ethics sets the ethical benchmark for the profession, and guides nurses in ethical analysis and decision making at the societal, organizational, and clinical levels. The code encompasses showing compassion and respect for the patient, their families, and communities in all circumstances while committing to providing patient-centered care. In addition, the code states that nurses must advocate for the patient by defending a cause or recommendation to protect their rights,...
4.6K
02:36Transfer RNA Synthesis
13.4K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
13.4K